Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Who's Who In Artificial Intelligence Drug Development

Executive Summary

Artificial intelligence companies focused on the life science sector have boomed in the past decade. Many of these firms are working with pharma partners and a small number are pursuing their own drug development pipelines.

You may also be interested in...



Finance Watch: Early-Stage Firms Gain Deal-Making Insight As Golumbeski Joins VC Ranks

Private Company Edition: Celgene's former top deal-maker George Golumbeski is now a life science business consultant and venture partner at ARCH. Also, a VC investment surge portends another big year for biopharma, including $85m for Ansun and $66m for FogPharma.

What's Next For Artificial Intelligence In The Clinic?

Numerate CEO Guido Lanza talks to Scrip about how artificial Intelligence, or AI, has been quietly used by some drug developers for the last decade, but its use is now rocketing. Also, what is next for AI in pharma?

Novartis CEO-Designate Set To Bring More Automation To Drug Discovery

Vasant Narasimhan, who is replacing Joseph Jimenez as Novartis' CEO next year, is an advocate of automation and artificial intelligence in future drug discovery.

Topics

Related Companies

UsernamePublicRestriction

Register

SC100494

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel